Targeted gene modification of hematopoietic progenitor cells in mice following systemic administration of a PNA-peptide conjugate

Molecular Therapy

Volumn 20, Issue 1, 2012, Pages 109-118

  Rogers, Faye A ^a   Lin, Sharon S ^a   Hegan, Denise C ^a   Krause, Diane S ^a   Glazer, Peter M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTENNAPEDIA PEPTIDE NUCLEIC ACID CONJUGATE; PEPTIDE NUCLEIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CELL DIFFERENTIATION; CELL LINEAGE; CELL RENEWAL; CONJUGATION; CONTROLLED STUDY; COVALENT BOND; EX VIVO GENE TRANSFER; FEMALE; GENE TARGETING; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IN VIVO STUDY; MINIMALLY INVASIVE PROCEDURE; MOUSE; NONHUMAN; SITE DIRECTED MUTAGENESIS; STEM CELL GENE THERAPY; STEM CELL MOBILIZATION; TISSUE DISTRIBUTION;

MUS;

EID: 84856964238     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.163     Document Type: Article

References (42)

1. Biffi, A and Cesani, M (2008). Human hematopoietic stem cells in gene therapy: preclinical and clinical issues. Curr Gene Ther 8: 135-146.
2. Bukanov, NO, Demidov, VV, Nielsen, PE and Frank-Kamenetskii, MD (1998). PDloop: a complex of duplex DNA with an oligonucleotide. Proc Natl Acad Sci USA 95: 5516-5520.
3. Nielsen, PE, Egholm, M and Buchardt, O (1994). Peptide nucleic acid (PNA). A DNA mimic with a peptide backbone. Bioconjug Chem 5: 3-7. (Pubitemid 2043873)
4. Praseuth, D, Grigoriev, M, Guieysse, AL, Pritchard, LL, Harel-Bellan, A, Nielsen, PE et al. (1996). Peptide nucleic acids directed to the promoter of the alpha-chain of the interleukin-2 receptor. Biochim Biophys Acta 1309: 226-238. (Pubitemid 26408289)
5. Janowski, BA, Kaihatsu, K, Huffman, KE, Schwartz, JC, Ram, R, Hardy, D et al. (2005). Inhibiting transcription of chromosomal DNA with antigene peptide nucleic acids. Nat Chem Biol 1: 210-215.
6. Hu, J and Corey, DR (2007). Inhibiting gene expression with peptide nucleic acid (PNA)-peptide conjugates that target chromosomal DNA. Biochemistry 46: 7581-7589. (Pubitemid 46986382)
7. Rogers, FA, Vasquez, KM, Egholm, M and Glazer, PM (2002). Site-directed recombination via bifunctional PNA-DNA conjugates. Proc Natl Acad Sci USA 99: 16695-16700. (Pubitemid 36034035)
8. Lonkar, P, Kim, KH, Kuan, JY, Chin, JY, Rogers, FA, Knauert, MP et al. (2009). Targeted correction of a thalassemia-associated beta-globin mutation induced by pseudocomplementary peptide nucleic acids. Nucleic Acids Res 37: 3635-3644.
9. Chin, JY, Kuan, JY, Lonkar, PS, Krause, DS, Seidman, MM, Peterson, KR et al. (2008). Correction of a splice-site mutation in the beta-globin gene stimulated by triplexforming peptide nucleic acids. Proc Natl Acad Sci USA 105: 13514-13519.
10. Wu, Q, Gaddis, SS, MacLeod, MC, Walborg, EF, Thames, HD, DiGiovanni, J et al. (2007). High-affinity triplex-forming oligonucleotide target sequences in mammalian genomes. Mol Carcinog 46: 15-23. (Pubitemid 46095229)
11. Vivès, E, Brodin, P and Lebleu, B (1997). A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272: 16010-16017. (Pubitemid 27265584)
12. Bongartz, JP, Aubertin, AM, Milhaud, PG and Lebleu, B (1994). Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res 22: 4681-4688. (Pubitemid 24354801)
13. Mäe, M and Langel, U (2006). Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr Opin Pharmacol 6: 509-514. (Pubitemid 44340662)
14. Manceur, A, Wu, A and Audet, J (2007). Flow cytometric screening of cell-penetrating peptides for their uptake into embryonic and adult stem cells. Anal Biochem 364: 51-59. (Pubitemid 46497956)
15. Derossi, D, Joliot, AH, Chassaing, G and Prochiantz, A (1994). The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269: 10444-10450. (Pubitemid 24198241)
16. Rogers, FA, Manoharan, M, Rabinovitch, P, Ward, DC and Glazer, PM (2004). Peptide conjugates for chromosomal gene targeting by triplex-forming oligonucleotides. Nucleic Acids Res 32: 6595-6604. (Pubitemid 40220371)
17. Faruqi, AF, Egholm, M and Glazer, PM (1998). Peptide nucleic acid-targeted mutagenesis of a chromosomal gene in mouse cells. Proc Natl Acad Sci USA 95: 1398-1403. (Pubitemid 28103403)
18. Hamilton, SE, Simmons, CG, Kathiriya, IS and Corey, DR (1999). Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem Biol 6: 343-351. (Pubitemid 29363167)
19. Faruqi AF, Egholm M and Glazer PM (1998). Peptide nucleic acid-targeted mutagenesis of a chromosomal gene in mouse cells. Proc Natl Acad Sci USA 95: 1398-1403. (Pubitemid 28103403)
20. McMahon, BM, Mays, D, Lipsky, J, Stewart, JA, Fauq, A and Richelson, E (2002). Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration. Antisense Nucleic Acid Drug Dev 12: 65-70. (Pubitemid 34627601)
21. Vasquez, KM, Narayanan, L and Glazer, PM (2000). Specific mutations induced by triplex-forming oligonucleotides in mice. Science 290: 530-533.
22. Narayanan, L, Fritzell, JA, Baker, SM, Liskay, RM and Glazer, PM (1997). Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2. Proc Natl Acad Sci USA 94: 3122-3127. (Pubitemid 27157274)
23. Shultz, LD, Lyons, BL, Burzenski, LM, Gott, B, Chen, X, Chaleff, S et al. (2005). Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174: 6477-6489. (Pubitemid 40663843)
24. Lucarelli, G, Galimberti, M, Giardini, C, Polchi, P, Angelucci, E, Baronciani, D et al. (1998). Bone marrow transplantation in thalassemia. The experience of Pesaro. Ann N Y Acad Sci 850: 270-275.
25. Sodani, P, Isgrò, A, Gaziev, J, Polchi, P, Paciaroni, K, Marziali, M et al. (2010). Purified T-depleted, CD34+ peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia. Blood 115: 1296-1302.
26. Hsieh, MM, Kang, EM, Fitzhugh, CD, Link, MB, Bolan, CD, Kurlander, R et al. (2009). Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 361: 2309-2317.
27. Xu, XS, Glazer, PM and Wang, G (2000). Activation of human gamma-globin gene expression via triplex-forming oligonucleotide (TFO)-directed mutations in the gamma-globin gene 5' flanking region. Gene 242: 219-228. (Pubitemid 30064507)
28. Svasti, S, Suwanmanee, T, Fucharoen, S, Moulton, HM, Nelson, MH, Maeda, N et al. (2009). RNA repair restores hemoglobin expression in IVS2-654 thalassemic mice. Proc Natl Acad Sci USA 106: 1205-1210.
29. Wu, LC, Sun, CW, Ryan, TM, Pawlik, KM, Ren, J and Townes, TM (2006). Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood 108: 1183-1188. (Pubitemid 44232013)
30. Chang, JC, Ye, L and Kan, YW (2006). Correction of the sickle cell mutation in embryonic stem cells. Proc Natl Acad Sci USA 103: 1036-1040. (Pubitemid 43212217)
31. Goncz, KK, Prokopishyn, NL, Abdolmohammadi, A, Bedayat, B, Maurisse, R, Davis, BR et al. (2006). Small fragment homologous replacement-mediated modification of genomic beta-globin sequences in human hematopoietic stem/progenitor cells. Oligonucleotides 16: 213-224. (Pubitemid 44763316)
32. Miccio, A, Cesari, R, Lotti, F, Rossi, C, Sanvito, F, Ponzoni, M et al. (2008). In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proc Natl Acad Sci USA 105: 10547-10552.
33. Pawliuk, R, Westerman, KA, Fabry, ME, Payen, E, Tighe, R, Bouhassira, EE et al. (2001). Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294: 2368-2371. (Pubitemid 33140563)
34. Perumbeti, A, Higashimoto, T, Urbinati, F, Franco, R, Meiselman, HJ, Witte, D et al. (2009). A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood 114: 1174-1185.
35. Adler, BK, Salzman, DE, Carabasi, MH, Vaughan, WP, Reddy, VV and Prchal, JT (2001). Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 97: 3313-3314.
36. Grigg, AP (2001). Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. Blood 97: 3998-3999.
37. Segal, BH, Leto, TL, Gallin, JI, Malech, HL and Holland, SM (2000). Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 79: 170-200. (Pubitemid 30327531)
38. Seger, RA, Gungor, T, Belohradsky, BH, Blanche, S, Bordigoni, P, Di Bartolomeo, P et al. (2002). Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood 100: 4344-4350. (Pubitemid 35429672)
39. Holland, SM (2010). Chronic granulomatous disease. Clin Rev Allergy Immunol 38: 3-10.
40. Johnston, RB 3rd, Harbeck, RJ and Johnston, RB Jr (1985). Recurrent severe infections in a girl with apparently variable expression of mosaicism for chronic granulomatous disease. J Pediatr 106: 50-55. (Pubitemid 15189907)
41. Woodman, RC, Newburger, PE, Anklesaria, P, Erickson, RW, Rae, J, Cohen, MS et al. (1995). A new X-linked variant of chronic granulomatous disease characterized by the existence of a normal clone of respiratory burst-competent phagocytic cells. Blood 85: 231-241.
42. Malech, HL, Maples, PB, Whiting-Theobald, N, Linton, GF, Sekhsaria, S, Vowells, SJ et al. (1997). Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci USA 94: 12133-12138. (Pubitemid 27467855)